Related Experiment Video
Updated: Mar 25, 2026

Co-immunoprecipitation Assay Using Endogenous Nuclear Proteins from Cells Cultured Under Hypoxic Conditions
Published on: August 2, 2018
A hidden aggregation-prone structure in the heart of hypoxia inducible factor prolyl hydroxylase
Hamid Hadi-Alijanvand1,2, Elizabeth A Proctor3, Feng Ding4,5
1Department of Biological Sciences, Institute for Advanced Studies in Basic Sciences (IASBS), Zanjan, Iran.
Abstract:
Prolyl hydroxylase domain-containing protein 2 (PHD2), as one of the most important regulators of angiogenesis and metastasis of cancer cells, is a promising target for cancer therapy drug design. Progressive studies imply that abnormality in PHD2 function may be due to misfolding. Therefore, study of the PHD2 unfolding pathway paves the way for a better understanding of the influence of PHD2 mutations and cancer cell metabolites on the protein folding pathway. We study the unfolding of the PHD2 catalytic domain using differential scanning calorimetry (DSC), fluorescence spectroscopy, and discrete molecular dynamics simulations (DMD). Using computational and experimental techniques, we find that PHD2 undergoes four transitions along the thermal unfolding pathway. To illustrate PHD2 unfolding events in atomic detail, we utilize DMD simulations. Analysis of computational results indicates an intermediate species in the PHD2 unfolding pathway that may enhance aggregation propensity, explaining mutation-independent PHD2 malfunction.
Insights
Prolyl hydroxylase domain-containing protein 2 (PHD2) unfolding was studied to understand cancer. An intermediate species was found, explaining PHD2 malfunction independent of mutations.
Area of Science:
- Biochemistry
- Molecular Biology
- Cancer Research
Background:
- Prolyl hydroxylase domain-containing protein 2 (PHD2) is crucial in regulating cancer angiogenesis and metastasis.
- PHD2 dysfunction, potentially due to misfolding, is implicated in cancer development.
- Understanding PHD2's protein folding pathway is vital for cancer therapy drug design.
Purpose of the Study:
- To investigate the thermal unfolding pathway of the PHD2 catalytic domain.
- To elucidate the atomic-level events during PHD2 unfolding.
- To understand how mutations and metabolites affect PHD2 folding.
Main Methods:
- Differential Scanning Calorimetry (DSC) for thermal unfolding.
- Fluorescence spectroscopy for structural changes.
- Discrete Molecular Dynamics (DMD) simulations for atomic detail.
Main Results:
- PHD2 exhibits four distinct transitions during thermal unfolding.
- DMD simulations revealed an intermediate species in the unfolding pathway.
- This intermediate may increase protein aggregation, leading to malfunction.
Conclusions:
- PHD2 unfolding is a complex process with identifiable intermediate states.
- The identified intermediate species offers a potential explanation for mutation-independent PHD2 malfunction in cancer.
- Targeting PHD2 folding pathways could be a novel therapeutic strategy for cancer.
More Related Videos
Related Concept Videos
Regulation of Angiogenesis and Blood Supply
Molecular Chaperones and Protein Folding
The...
Hypoxia
Types of Hypoxia
There are four primary types of hypoxia, each resulting from a different cause:
1. Anemic hypoxia: This type occurs due to insufficient oxygen delivery caused by a lack of red blood cells (RBCs) or RBCs with abnormal or...
Protein Folding
Protein Structure Is Critical to Its Biological Function
Proteins perform a wide range of biological functions such as catalyzing chemical reactions, providing...
Protein Folding
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....

